These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36153542)

  • 1. Response to comment on "Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma".
    Xie YF; Liu YL; Guo XG
    World J Surg Oncol; 2022 Sep; 20(1):306. PubMed ID: 36153542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on "Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma".
    Sharma G
    World J Surg Oncol; 2021 Aug; 19(1):237. PubMed ID: 34380515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled analysis of Xpert Bladder Cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma.
    Liu YL; Wang XL; Yang XH; Wu XH; He GX; Xie LM; Cao XJ; Guo XG
    World J Surg Oncol; 2021 Feb; 19(1):42. PubMed ID: 33563292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.
    Sharma G; Sharma A; Krishna M; Devana SK; Singh SK
    Urol Oncol; 2022 Apr; 40(4):163.e1-163.e9. PubMed ID: 34535354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
    D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
    J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
    Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
    Cancel-Tassin G; Roupret M; Pinar U; Gaffory C; Vanie F; Ondet V; Compérat E; Cussenot O
    World J Urol; 2021 Sep; 39(9):3329-3335. PubMed ID: 33770241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.
    Hurle R; Casale P; Saita A; Colombo P; Elefante GM; Lughezzani G; Fasulo V; Paciotti M; Domanico L; Bevilacqua G; Maffei D; Diana P; Frego N; Sandri MT; Maura F; Morenghi E; Buffi NM; Guazzoni G; Lazzeri M
    World J Urol; 2020 Sep; 38(9):2215-2220. PubMed ID: 31691083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Lu X; Simon IM; Campbell SA; Bates MP; Higuchi RG; Witjes JA
    Eur Urol Oncol; 2021 Feb; 4(1):93-101. PubMed ID: 33004290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker.
    Elsawy AA; Awadalla A; Abdullateef M; Ahmed AE; Abol-Enein H
    Urol Oncol; 2021 Jul; 39(7):437.e11-437.e19. PubMed ID: 33785220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
    Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
    Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
    Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
    Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of HOX B13 expression in urinary bladder cancer progression.
    Marra L; Cantile M; Scognamiglio G; Perdonà S; La Mantia E; Cerrone M; Gigantino V; Cillo C; Caraglia M; Pignata S; Facchini G; Botti G; Chieffi S; Chieffi P; Franco R
    Curr Med Chem; 2013 Feb; 20(6):833-9. PubMed ID: 23276138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C
    Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
    Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
    Laukhtina E; Shim SR; Mori K; D'Andrea D; Soria F; Rajwa P; Mostafaei H; Compérat E; Cimadamore A; Moschini M; Teoh JY; Enikeev D; Xylinas E; Lotan Y; Palou J; Gontero P; Babjuk M; Witjes JA; Kamat AM; Roupret M; Shariat SF; Pradere B;
    Eur Urol Oncol; 2021 Dec; 4(6):927-942. PubMed ID: 34753702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The fluorescent hybridization in situ as applied in diagnostics of urinary bladder cancer].
    Savostikova MV; Volchenko NN; Rusakov IG; Borisova OV; Golovashchenko MP
    Klin Lab Diagn; 2011 Aug; (8):38-40. PubMed ID: 22164416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.